The degradation of intravenously administered chondroitin sulphate-peptide, obtained by trypsin digestion of rat cartilage preparations labelled in vitro with 35S (and, in some cases, with 3H), was studied in rats. As with free chains of chondroitin sulphate, the major site of accumulation and degradation in the body was the liver, although peptide-linked chains were taken up more rapidly than free chains. In the first 2h after intravenous injection of a chondroitin sulphate-peptide fraction, labelled macromolecular components were excreted in the urine. These were shown to be chondroitin sulphate-peptide of the same degree of sulphation but of smaller average size than the injected material. A similar observation was made when free chains of chondroitin sulphate from the same source were administered intravenously. An isolated perfused rat kidney failed to de-sulphate circulating chondroitin sulphate-peptide, but a component of lower average molecular weight was excreted in the urine. When a chondroitin sulphate-peptide fraction of relatively larger hydrodynamic volume was administered, very little chondroitin sulphate appeared in the urine in the first 2h. It was concluded that, depending on size and/or peptide content, the chondroitin sulphate-peptide released from connective tissues into the circulation would probably be subjected to one of two alternative fates. The smaller fragments are more likely to be excreted in the urine, whereas the larger ones are taken up by the liver and there degraded to inorganic sulphate and undefined carbohydrate components.
roitin 4[p5S] sulphate are injected intravenously into rats, significant amounts are taken up by liver lysosomes and degraded with the release of inorganic [35S] sulphate. The metabolism of intact (35S]proteoglycan in the guinea-pig has been studied by Revell & Muir (1972) , who found that more radioactive label was retained in the body than when free chains of chondroitin sulphate were administered, but that some was excreted in the urine in the form of free chondroitin sulphate, presumably after proteolytic degradation. By contrast, in the rat, excretion of chondroitin sulphate was not observed to any extent when proteoglycan from rat xiphoid cartilage was freed from components of lower molecular weight before injection (Wood et al., 1975) .
The turnover of chondroitin sulphate in vivo is thought to involve, in addition to intracellular degradation in the connective tissue itself (Amado et al., 1974) , the release of partially degraded proteoglycan molecules into the circulation. These fragments contain more than one chondroitin sulphate chain attached to lengths ofcommon peptide (Wasteson et al., 1972) .
The purpose of the present investigation was to determine the sites ofdegradation and excretion in the rat of chondroitin sulphate-peptide prepared by trypsin digestion ofrat cartilage. This form ofproteolytic digestion was chosen so as to produce degraded proteoglycan similar to that released normally into the circulation after cathepsin action (Morrison et al., 1973; Woessner, 1973) . To follow the fate of carbohydrate moieties, chondroitin sulphate preparations were labelled with 3H (in the galactosamine residue) as well as 35S (in the ester sulphate group).
Materials and Methods
The experimental and analytical techniques were those described by Wood et al. (1973a,b) Labelling and isolation ofchondroitin sulphate-peptide from cartilage Sliced sections from rat xiphoid cartilage (approx. 1 g) were incubated for 23h at 37°C in 4ml of KrebsRinger bicarbonate solution, pH7.3 (Umbreit et al., 1964) , containing carrier-free Na235SO4 (80pCi/ml) as described by Hardingham & Muir (1972) . Sections from rat rib cartilage (approx. 2g) were similarly incubated in 4ml of solution containing both carrierfree Na235SO4 (25, uCi/ml) and D-[6-3H]glucosamine hydrochloride (20pCi/ml). The washed cartilage sections were extracted with 4M-guanidinium chloride and intact proteoglycan was isolated as reported by Wood et al. (1975 Cl-form; 200400 mesh; Sigma Chemical Co., Kingston-upon-Thames, Surrey, U.K.), which had been previously equilibrated with 1 M-NaCl. The column was washed with 1 M-NaCl (the effluent was discarded) and eluted with 2M-NaCl in separate portions making a total of 3 bed volumes. The labelled chondroitin sulphate-peptide was precipitated from the combined 2M-NaC1 effluent by addition of 4vol. of ethanol, and was collected by centrifuging after storage at 4'C to allow the precipitate to flocculate.
Chondroitin sulphate-peptide preparations from rat xiphoid and rib cartilage contained 0.98-0.99mol of uronic acid, 0.01 mol of glucosamine, 0.34mol of amino acid residues and 0.92-0.94mol of ester sulphate/mol of galactosamine. Chondroitin 4-sulphate [estimated as a fraction of total chondroitin sulphate by method III of Saito etal. (1968) ] was 93 % of the product from xiphoid cartilage residues and 91 % of that from rib. Osmotic-pressure and equilibrium-ultracentrifuge measurements (Wusteman & Davidson, 1975) indicated that it contained 2.6 times the average number of uronic acid residues in single chains of chondroitin sulphate isolated from the same cartilage source by papain digestion, and that it was predominantly a mixture of two-chain and fourchain units. The preparation had a number-average mol.wt. of 24750 (determined by osmometry) and a weight-average mol.wt. of 28200 (determined by sedimentation-equilibrium centrifugation).
The specific radioactivity of the 35S-labelled product from xiphoid cartilage was in the range 2.4-9.1 uCi/4umol of uronic acid. From rib cartilage the double-labelled product contained 1.42,uCi of 35S and 0.31 pCi of 3H radioactivity/,cmol of uronic acid.
Hexosamine analysis showed that over 98% of the 3H was associated with galactosamine residues.
Fractionation of double-labelled chondroitin sulphatepeptide by gel chromatography A preparation of 3H-and 35S-labelled chondroitin sulphate-peptide obtained from 0.5g of rib cartilage dissolved in 3ml of 0.2M-NaCl, was applied to a column (580mmx9mm) of Sephadex G-200 [Pharmacia (G.B.) Ltd., London W.5, U.K.] and eluted with 0.2M-NaCl at a flow rate of 4ml/h. The effluent from 14-17ml (fraction A) and 18-30ml (fraction B) (see Fig. 3 ) were pooled and precipitated by addition of ethanol (4vol. (10041) were added to an equal volume of 0.1 M-sodium acetate buffer, pH6.3, containing 0.002M-L-cysteine hydrochloride and 0.005M-EDTA, and papain (1 mg; BDH) was added. The mixture was incubated at 60°C for 12h and, as a control, chondroitin [35S]sulphate-peptide was dissolved in a control urine and subjected to the same digestion. These digests were stored at -20'C until samples (100,ul) were analysed by gel chromatography on Sephadex G-200.
Isolated perfused rat kidney preparation
The apparatus was essentially that for perfusing the isolated liver (Wood et al., 1973b) , except that an additional peristaltic pump was included in the system. This pump supplied perfusate directly to the kidney and the flow was adjusted to maintain a pressure of 8-16kPa (604120mmHg). The rat donating the kidney was anaesthetized with Nembutal, and the right kidney was isolated in situ as described by Curtis et al. (1969) . Chondroitin 4[35S]sulphate-peptide (14puCi; 3.4mg dissolved in 3.3ml of 0.95% NaCI) was added to the perfusate (whole blood, 100ml) and the kidney was perfused at an average rate of 1.2ml/min (range 1.0-1.5ml/min) for 4h. Samples (2ml) of the perfusate were removed every 30min and the plasma was separated by centrifuging for 20min at 2000g at 4°C. Urine was collected over the 4h period, and continuous flow was maintained by the addition ofmannitol [0.5ml of 5 % (w/v) mannitol in 0.95 % NaCI] 2.5h after the start of perfusion.
Results
The distribution and metabolic fate of chondroitin
[35S]sulphate-peptide, derived from rat xiphoid cartilage by trypsin digestion, in the plasma and liver was compared with the results already reported for single chains of chondroitin 4-[35S]sulphate (Wood et al., 1973a) . Chondroitin [35S]sulphate-peptide was administered intravenously at a dose of 5.4mg/kg body wt. to a group of rats (340-360g body wt.) which were killed at intervals ranging from 30min to 6h. Blood plasma and liver tissue were isolated, digested with papain, and radioactivity was measured before and after precipitation of intact chondroitin sulphate with cetylpyridinium chloride and of inorganic sulphate with BaCl2. The remaining supernatant soluVol. 158 tion was assumed to contain any oligosaccharide produced during the degradation of chondroitin sulphate. The total recovery of injected radioactivity in plasma and liver was 49% at 30min, 22% at 1 h and falling thereafter to 7% at 6h. At 30min to 1 h after injection, the concentration of radioactivity in the plasma was 12-17% of that in the liver [by contrast, when single chains of chondroitin 4-[35S]sulphate were administered (Wood et al., 1973a) , the plasma radioactivity was 89-130% of that in the liver between 30min and 1 h after injection]. After 1 h had elapsed, the radioactivity in the plasma was predominantly inorganic sulphate (Fig. la) Void volume of the column (580mmx9mm) is indicated by V0. the plasma. By contrast, the liver contained both oligosaccharide and inorganic sulphate, whereas the amount of polymeric chondroitin sulphate decreased to 10-16% after 3h had elapsed (Fig. Ib) .
These results indicated that, as with free chains of chondroitin sulphate, the liver is the major site for depolymerization and desulphation of chondroitin sulphate-peptide. Evidence in support of this hypothesis was obtained by intravenous administration of chondroitin [35S] sulphate-peptide at 1.8mg/kg body wt. to hepatectomized rats (Wood et al., 1973a) . As with the free chains of chondroitin sulphate, removal of the liver prevented the desulphation of chondroitin sulphate-peptide, which was unchanged in the plasma (as estimated by gel chromatography on Sephadex G-200). It still accounted for 35 % of the injected radioactivity after 5h had elapsed. Some (22.5 %) of the chondroitin sulphate-peptide administered to the hepatectomized rats was excreted in the urine within 5h, and gel chromatography indicated that this was of slightly lower molecular weight than the injected material. To investigate any possible role of the kidneys in producing this component, an isolated kidney from a rat was perfused with blood containing chondroitin 35Slsulphate-peptide (14.uCi; 3.4mg). Elution profiles obtained by gel chromatography of the urine and plasma recovered after 4h perfusion (Fig. 2) showed no peak of inorganic [35S] sulphate, which, when present, was eluted at VO = 41 ml. The elution profile ofthe labelled material in the plasma was similar to that of the unchanged polymer, whereas the labelled material in the urine, though still macromolecular, emerges at a larger elution volume. This implies either that a portion had been slightly degraded in passage through the kidneys or that a subfraction of lower molecular weight in the plasma had been preferentially filtered by the kidneys.
To resolve these two possibilities, the 35S and 3H-labelled chondroitin sulphate-peptide from rat rib was fractionated by gel chromatography on a column of Sephadex G-200 and arbitrarily divided into fractionsAand B (see the Materials and Methods section). These differed in hydrodynamic size (Fig. 3a) and, on papain digestion, yielded chondroitin sulphate chains, which gaveelutionprofiles (Fig. 3b) Of the total radioactivity injected in the form of 35S, approximately half was retained in the body after 6h. The bulk was excreted in the urine and less than 4 % in the bile. In all cases the overall excretion of 3H in the urine was lower than that of 35S ( Fig. 4 . Gel chromatography on Sephadex G-200 ofurine from rats with canmdlated ureters collected after injection of double labelled chondroitin sulphate-peptide subfractions The column was eluted with 0.2M-NaCl. Elution profiles of 3H-(o) and 35S-(0) labelled metabolites in urine collected in the first hour after injection of (a) fraction A and (b) fraction B and in the second hour after injection of (c) fraction A and (d) fraction B, and applied to Sephadex G-200. The void volume V0 of the column (580mmx9mm) is indicated by the arrow. fraction B (Figs. 4b and 4d) , and it was the sole form in which the 35S label of fraction A emerged after the first hour.
It was during the first hour that the most noteworthy differences appeared in the excretion pattern of radioactivity from fraction A and from the two preparations of lower molecular weight. Very little 35S label was detected in the urine collected in the first 1976
F~~~~.- The macromolecular fraction in the urine was isolated by gel chromatography on Sephadex G-200 as shown in Fig. 4 (Fig. 5) shows that the macromolecular 35S-labelled components in the urine are still susceptible to papain digestion and thus are unlikely to have resulted from proteolytic degradation of the circulating chondroitin sulphate-peptide.
Discussion
The initial observations with 35S-labelled chondroitin sulphate-peptide suggest that linking two to four chains of chondroitin sulphate via a common peptide core does not greatly affect its fate in the liver.
As shown in Fig. 1 , the relative amount of polymer in liver decreased soon after administration and was replaced by inorganic sulphate and an ester sulphate fraction presumed to be oligosaccharide. This latter component was not seen in the plasma, where inorganic sulphate rapidly replaced the polymer as the major radioactive material. In this respect, chondroitin sulphate-peptide preparations share the same fate as free chondroitin sulphate chains (Wood et al., 1973a,b) , with the one notable difference that they disappear more rapidly from the circulation.
In contrast with the liver, where rapid uptake and degradation take place, the kidneys seem to function chiefly in filtering the smaller components, whether peptide-bound or not, and excreting them in the urine. Whereas macromolecular proteoglycan (Wood et al., 1975) and the larger of the chondroitin sulphatepeptide subfractions are retained in the circulation, the smaller peptide-bound chondroitin sulphate chains and single chains are likely to be excreted unchanged, and so avoid uptake by the liver. The possibility of proteolytic digestion in the kidneys cannot be excluded entirely, but it is unnecessary to invoke this to account for the observed size distribution of urinary chondroitin sulphate.
Greater size, or the presence of a larger peptide component, seems also to favour uptake by the liver. Radioactive components were more rapidly taken up by the liver from the plasma during the time-course experiments after injection of chondroitin sulphatepeptide than in those reported earlier (Wood et al., 1973a) in which free chains of chondroitin sulphate were used, even allowing for the filtration of smaller components bythe kidneys. The uptake of circulating chondroitin sulphate by liver cells presumably involves absorptive pinocytosis and Kresse et al. (1975) have reported that absorptive pinocytosis of proteoglycans by cultured fibroblasts is markedly decreased by degradation of the protein core.
In 
